Revenue
1.24 billion USD
2024 Q1 · USD
Exact inputs and evidence
- Revenue: 1235000000 USD Source
Fundies. English
Hoth Therapeutics, Inc.
EDGAR44 filing records in this dataset, filed from 2018-10-10 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.
Latest quarter
- Cash and cash equivalents
- 7.89 million uref_2079664326 Source
Exact value
7891911 uref_2079664326
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 23.2 million uref_272751664 Source
Exact value
23184634 uref_272751664
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 2 of 11 periods available· newest 2025-12-31
- Net income: 2 of 11 periods available· newest 2025-12-31
- Operating cash flow: 2 of 11 periods available· newest 2025-12-31
- capital expenditure: No compatible figures in this window
- Total assets: Multiple units; comparison withheld· newest 2025-12-31
- Total liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Current assets: Multiple units; comparison withheld· newest 2025-12-31
- Current liabilities: Multiple units; comparison withheld· newest 2025-12-31
- Cash and cash equivalents: Multiple units; comparison withheld· newest 2025-12-31
- long term debt: No compatible figures in this window
- Shares outstanding: Multiple units; comparison withheld· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−uref_216149549 4.28 millionPrior period
−uref_216149549 8.19 million
–
Current period
−uref_216149549 12.47 million
–
Exact inputs and evidence
-12469302 − -8188300 = -4281002 uref_216149549
-8188300 uref_216149549 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-12469302 uref_216149549 · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−uref_216149549 2.83 millionPrior period
−uref_216149549 6.98 million
–
Current period
−uref_216149549 9.8 million
–
Exact inputs and evidence
-9803918 − -6978251 = -2825667 uref_216149549
-6978251 uref_216149549 · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-9803918 uref_216149549 · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Not enough comparable data to show this history.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value(uref_216149549) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Not enough comparable data to show this history.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2024 2024-01-01 – 2024-12-31 | −uref_216149549 8.19 million Exact valueExact value: -8188300 uref_216149549 Share or citeThe citation records this snapshot. The page link may show a newer release later. | −uref_216149549 6.98 million Exact valueExact value: -6978251 uref_216149549 Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2025-01-01 – 2025-12-31 | −uref_216149549 12.47 million Exact valueExact value: -12469302 uref_216149549 Share or citeThe citation records this snapshot. The page link may show a newer release later. | −uref_216149549 9.8 million Exact valueExact value: -9803918 uref_216149549 Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
44 filings · 1,659 latest values · 1,659 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001711786, 1711786, HOTH, RKTO, edgar:1711786
Also known as HOTH THERAPEUTICS, INC., HOTH THERAPEUTICS, INC., Hoth Therapeutics, Inc, Hoth Therapeutics, Inc., Rocket One Inc.